SEATTLE, March 21, 2014 /PRNewswire/ -- Omeros
Corporation (NASDAQ: OMER), a biopharmaceutical company committed
to discovering, developing and commercializing products focused on
inflammation, bleeding and disorders of the central nervous system,
today announced that Gregory A.
Demopulos, M.D., chairman and chief executive officer, will
present at the BioCentury Future Leaders in the Biotech Industry
Conference in New York next
week. The presentation is scheduled for Friday, March 28, 2014 at 9:00 a.m. EDT.
The presentation will be webcast. The live and archived webcasts
can be accessed on the "Events" page of the Company's website at
www.omeros.com.
About Omeros Corporation
Omeros is a clinical-stage
biopharmaceutical company committed to discovering, developing and
commercializing small-molecule and protein therapeutics targeting
inflammation, coagulopathies and disorders of the central nervous
system. Derived from its proprietary PharmacoSurgery®
platform, the Company's lead drug product, Omidria™
(OMS302) for lens replacement surgery, is currently under review
for marketing approval by both the US Food and Drug Administration
and the European Medicines Agency with US commercial launch planned
for the second half of 2014. Omeros' six other clinical programs
are focused on schizophrenia, Huntington's disease and cognitive
impairment; addictive and compulsive disorders; complement-related
diseases; and preventing problems associated with surgical
procedures. Omeros also has a proprietary GPCR platform, which is
making available an unprecedented number of new GPCR drug targets
and corresponding compounds to the pharmaceutical industry for drug
development.
SOURCE Omeros Corporation